Brief: FibroGen Announces Presentation Of Positive Interim Data From The Phase 1B Study Of F-3246 In Combination With Enzalutamide In Patients With MCRPC

Kyntra Bio

23/05/2024 23:54

May 23 (Reuters) - FibroGen Inc  FGEN.O :
    * FIBROGEN ANNOUNCES PRESENTATION OF POSITIVE INTERIM DATA
FROM
THE PHASE 1B STUDY OF FG-3246 (FOR46) IN COMBINATION WITH
ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRATION RESISTANT
PROSTATE CANCER (MCRPC) AT THE 2024 AMERICAN SOCIETY OF CLINICAL
ONCOLOGY ANNUAL MEETING
    * FIBROGEN INC - FG-3246 DEMONSTRATED AN ACCEPTABLE SAFETY
PROFILE
    * FIBROGEN- RECOMMENDED PHASE 2 DOSE OF FG-3246 SET AT 2.1
MG/KG
EVERY 3 WEEKS IN COMBINATION WITH ENZALUTAMIDE GIVEN AT STANDARD
DOSE OF 160 MG DAILY
    * FIBROGEN INC - ANTICIPATES INITIATION OF PHASE 2
MONOTHERAPY
DOSE OPTIMIZATION STUDY OF FG-3246 IN MCRPC IN SECOND HALF OF
2024

Source text for Eikon:  ID:nGNX5dX6Rj 
Further company coverage:  FGEN.O 

 ((Reuters.Briefs@thomsonreuters.com;))